[1]金 龙,于 娇,刘瑞廷,等.同步加量放射治疗在直肠癌新辅助放化疗中的临床效果观察[J].陕西医学杂志,2024,(9):1220-1223,1227.[doi:DOI:10.3969/j.issn.1000-7377.2024.09.014]
点击复制

同步加量放射治疗在直肠癌新辅助放化疗中的临床效果观察
分享到:

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年9期
页码:
1220-1223,1227
栏目:
临床研究
出版日期:
2024-09-05

文章信息/Info

作者:
金 龙1于 娇1刘瑞廷2王 青1张高飞1
(1.陕西省人民医院放疗科,陕西 西安 710068; 2.陕西省人民医院普外科,陕西 西安 710068)
关键词:
直肠癌 新辅助放化疗 同步加量 病理完全缓解 肿瘤退缩分级 急性不良反应
分类号:
R 735.37
DOI:
DOI:10.3969/j.issn.1000-7377.2024.09.014
文献标志码:
A
摘要:
目的:探讨同步加量(SIB)放射治疗对直肠癌新辅助放化疗(nCRT)患者早期疗效及急性不良反应的影响。方法:研究纳入Ⅱ-Ⅲ期直肠腺癌患者74例,根据放疗剂量分为SIB组(29例)和标准剂量组(45例)。比较两组病理完全缓解(pCR)率、肿瘤T/N降期率、肿瘤退缩分级(TRG)及急性不良反应。结果:SIB组和标准剂量组pCR率分别为24.14%和15.56%,肿瘤T/N降期率分别为62.07%/75.86%和53.33%/68.89%,两组比较无统计学差异(均P>0.05)。SIB组和标准剂量组肿瘤退缩良好(TRG0+1)率分别为58.62%及26.67%,SIB组高于标准剂量组(P<0.05)。两组急性不良反应比较无统计学差异(均P>0.05)。结论:SIB技术对于直肠癌新辅助放化疗是有效和安全的。

参考文献/References:

[1] RYAN R,GIBBONS D,HYLAND J M P,et al.Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J].Histopathology,2010,47(2):141-146.
[2] 王德康,鲁信军,李浩.术前不同途径新辅助化疗联合腹腔镜手术治疗直肠癌近远期效果临床研究[J].陕西医学杂志,2022,51(10):1240-1243.
[3] FOKAS E,APPELT A L,GLYNNE-JONES R,et al.International consensus recommendations on key outcome measures for organ preservation after(chemo)radiotherapy in patients with rectal cancer[J].Nature Reviews Clinical Oncology,2021,18(12):805-816.
[4] MINSKY B D.Progress in the treatment of locally advanced clinically resectable rectal cancer[J].Clinical Colorectal Cancer,2011,104:227-237.
[5] 赵稳,李智,杜记涛,等.直肠腺癌75例新辅助放化疗肿瘤退缩分级相关临床病理因素分析[J].中华肿瘤防治杂志,2021,28(1):73-78
[6] ORLANDI E,PALAZZI M,PIGNOLI E,et al.Radiobiological basis and clinical results of the simultaneous integrated boost(SIB)in intensity modulated radiotherapy(IMRT)for head and neck cancer:A review[J].Critical Reviews in Oncology Hemetology,2010,73(2):111-125.
[7] 钟亮,廖荣伟,刘清壮,等.调强适形放疗联合新辅助化疗治疗上下行型鼻咽癌疗效研究[J].陕西医学杂志,2020,49(8):964-968.
[8] LUPATTELLI M,MATRONE F,GAMBACORTA M A,et al.Preoperative intensity-modulated radiotherapy with a simultaneous integrated boost combined with capecitabine in locally advanced rectal cancer:Short-term results of a multicentric study[J].Radiation Oncology(London,England),2017,12(1):139.
[9] PICARDI V,MACCHIA G,CILLA S,et al.PO-0716:Preoperative chemoradiation with VMAT-SIB in rectal cancer:A phase Ⅱ study(grace-rectum-1)[J].Radiotherapy and Oncology,2016,16(1):16-22.
[10] CILLA S,DEODATO F,DIGESÙC,et al.Assessing the feasibility of volumetric-modulated arc therapy using simultaneous integrated boost(SIB-VMAT):An analysis for complex head-neck,high-risk prostate and rectal cancer cases[J].Medical Dosimetry,2014,39(1):108-116.
[11] JANKARASHVILI N,KAKHADZE S,TOPESHASHVILI M,et al.Neoadjuvant volumetric modulated arc radiochemotherapy with a simultaneous integrated boost technique compared to standard chemoradiation for locally advanced rectal cancer[J].Turkish Journal of Medical Sciences,2019,49(5):1484-1489.
[12] YAMASHITA H,ISHIHARA S,NOZAWA H,et al.Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts(SIB-VMAT)of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers:A propensity score case-matched analysis[J].Radiation Oncology,2017,12(1):156.
[13] 中国医师协会结直肠肿瘤专委会放疗专委会,章真,田野,等.直肠癌术前/术后适形/调强放疗靶区勾画共识与图谱[J].中华放射肿瘤学杂志,2018,27(3):8.
[14] HODAPP N.The ICRU report 83:Prescribing,recording and reporting photon-beam intensity-modulated radiation therapy(IMRT)[J].Strahlentherapieund Onkologie,2012,188(1):97-99.
[15] COX J D,STETZ J A,PAJAK T F.Toxicity criteria of the radiation therapy oncology group(RTOG)and the european organization for research and treatment of cancer(EORTC)[J].Int J Radiat Oncol Biol Phys,2015,31(5):1341-1346.
[16] 何婉,HOENDERVANGERS S,BURBACH J P M,等.局部进展期直肠癌不同新辅助治疗后的病理完全缓解:一项系统综述和Meta分析[J].结直肠肛门外科,2021,27(3):268-269.
[17] 李心翔,李大卫.直肠癌新辅助放化疗临床完全缓解后处理的争议与共识[J].中国实用外科杂志,2020,40(3):325-329.
[18] 中国直肠癌新辅助治疗后等待观察数据库研究协作组,中国医师协会外科医师分会中国医师协会肛肠医师分会,中华医学会外科学分会结直肠外科学组,等.直肠癌新辅助治疗后等待观察策略专家共识(2024版)[J].中华胃肠外科杂志,2024,27(4):301-315.
[19] ATWELL D,ELKS J,CAHILL K,et al.A review of modern radiation therapy dose escalation in locally advanced head and neck cancer-sciencedirect[J].Clinical Oncology,2020,32(5):330-341.
[20] 同步加量放疗治疗不可手术食管鳞癌的远期疗效及安全性:泛京津冀食管肿瘤多中心协作组多中心回顾性研究(3JECROG R-05)[J].中华肿瘤杂志,2021,43(8):8.
[21] HEARN N,ATWELL D,CAHILL K,et al.Neoadjuvant radiotherapy dose escalation in locally advanced rectal cancer:A systematic review and meta-analysis of modern treatment approaches and outcomes[J].Clinical Oncology,2020,33(1):e1-e14.
[22] FERNANDEZ L M,SÃOJULIÃO G P,FIGUEIREDO N L,et al.Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the international watch amp; wait database:A retrospective,international,multicentre registry study[J].The Lancet Oncology,2020,22(1):43-50.
[23] GENG J H,ZHANG Y Z,LI Y H,et al.Preliminary results of simultaneous integrated boost intensity-modulated radiation therapy based neoadjuvant chemoradiotherapy on locally advanced rectal cancer with clinically suspected positive lateral pelvic lymph nodes[J].Ann Transl Med,2021,9(3):217.
[24] 彭俊杰,朱骥,刘方奇,等.中国局部进展期直肠癌诊疗专家共识[J].中国癌症杂志,2017,27(1):41-80.
[25] TRAKARNSANGA A,GONEN M,SHIA J,et al.Comparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatment[J].J Natl Cancer Inst,2014,106(10):248.
[26] BEDDY D,HYLAND J M P,WINTER D C,et al.A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy[J].Ann Surg Oncol,2008,15(12):3471-3477.
[27] 刘其腾,陈静,贾宝庆,等.局部中晚期直肠癌术前新辅助同期加量IMRT联合术前化疗的Ⅱ期临床研究[J].中华放射肿瘤学杂志,2017,26(3):302-306.
[28] BUT-HADZIC J,ANDERLUH F,BRECELJ E,et al.Acute toxicity and tumor response in locally advanced rectal cancer after preoperative chemoradiation therapy with shortening of the overall treatment time using intensity-modulated radiation therapy with simultaneous integrated boost:A phase 2 trial[J].International Journal of Radiation Oncology,Biology,Physics,2016,96(5):1003-1010.
[29] 崔磊,徐晓南,曾星,等.同步加量调强放疗技术在直肠癌术前同期放化疗的应用效果[J].中国医药科学,2021,11(10):187-190,194.
[30] 曾铭玥,冯林春,贾宝庆,等.局部进展期中低位直肠癌患者术前同期加量调强放疗联合化疗的疗效观察[J].解放军医学院学报,2020,41(10):953-958.

相似文献/References:

[1]周兴伟,黄雪,张坤,等.直肠腔内360°及三维超声检查在直肠癌诊断中的价值[J].陕西医学杂志,2016,(09):1181.
[2]张永宏,刘 磊,陆王锋.直肠癌Dixon术后不同入路引流方式临床研究[J].陕西医学杂志,2019,(4):479.
[3]王 军,欧 理△,周清梓,等.直肠癌患者术后血清补体C3、C4水平变化及其与术后疼痛的相关性研究*[J].陕西医学杂志,2019,(8):984.
 WANG Jun,OU Li,ZHOU Qingzi,et al.Changes of serum complement C3 and C4 in patients with rectal cancer after operation and their relationship with postoperative pain[J].,2019,(9):984.
[4]普彦淞,刘 栋,毛智军△,等.乙状结肠腹膜外造口一期乳头成形术联合生物补片盆底重建在腹腔镜直肠癌根治术中的临床应用价值评估*[J].陕西医学杂志,2019,(12):1688.
[5]王德康,鲁信军,李 浩.术前不同途径新辅助化疗联合腹腔镜手术治疗直肠癌近远期效果临床研究[J].陕西医学杂志,2022,51(10):1240.[doi:DOI:10.3969/j.issn.1000-7377.2022.10.015]
 WANG Dekang,LU Xinjun,LI Hao.Short-term and long-term effects of preoperative neoadjuvant chemotherapy combined with laparoscopic surgery for rectal cancer by different routes[J].,2022,51(9):1240.[doi:DOI:10.3969/j.issn.1000-7377.2022.10.015]

备注/Memo

备注/Memo:
基金项目:陕西省重点研发计划项目(2023-YBSF-329); 陕西省人民医院科技人才支持计划项目(2022JY-08); 陕西省人民医院科技发展孵化基金资助项目(2022YJY-01)
更新日期/Last Update: 2024-09-04